Adverse effect of hydralazine in patients with primary pulmonary hypertension.
Adverse effect of hydralazine in patients with primary pulmonary hypertension.
复制标题
肼屈嗪对原发性肺动脉高压患者的不良反应。
DOI：
10.1001/jama.1982.03320470058033
复制
发表时间：
1982
期刊：
影响因子：
--
通讯作者：
H. Winer
中科院分区：
文献类型：
--
作者：
I. Kronzon;M. Cohen;H. Winer
盐酸肼苯哒嗪已被推荐作为原发性肺动脉高压的治疗药物。两名接受这种治疗的患者出现肺动脉压进一步升高和临床恶化。这种不良反应的机制是全身血管阻力降低，伴随心输出量增加，而肺血管阻力没有下降。建议对接受血管扩张剂治疗的原发性肺动脉高压患者进行血流动力学监测。（JAMA 1982;247：3112-3114）
Hydralazine hydrochloride has been recommended as a treatment for primary pulmonary hypertension. Two patients who were so treated experienced further elevation of the pulmonary artery pressure and clinical deterioration. The mechanism of this adverse effect was a decrease of systemic vascular resistance attended by an increase in cardiac output without a fall in the pulmonary vascular resistance. Hemodynamic monitoring is advised in patients undergoing vasodilator therapy for primary pulmonary hypertension. ( JAMA 1982;247:3112-3114)